TY - JOUR
T1 - Curcumin prevents and reverses murine cardiac hypertrophy
AU - Li, Hong Liang
AU - Liu, Chen
AU - De Couto, Geoffrey
AU - Ouzounian, Maral
AU - Sun, Mei
AU - Wang, Ai Bing
AU - Huang, Yue
AU - He, Cheng Wei
AU - Shi, Yu
AU - Chen, Xin
AU - Nghiem, Mai P.
AU - Liu, Youan
AU - Chen, Manyin
AU - Dawood, Fayez
AU - Fukuoka, Masahiro
AU - Maekawa, Yuichiro
AU - Zhang, Liyong
AU - Leask, Andrew
AU - Ghosh, Asish K.
AU - Kirshenbaum, Lorrie A.
AU - Liu, Peter P.
N1 - Funding Information:
The authors are grateful to Dr Leif Kongerslev and his team from Novo Nordisk for providing the Factor VII producer BHK cell clone, the Factor VII ELISA kit and the perfusion system. For the regulated clones and expertise the authors thank Dr Peter Mueller and Dr Hansjörg Hauser at GBF. The authors are also grateful to Maria do Rosário Clemente from IBET/ITQB for technical support. The authors acknowledge and appreciate the financial support received from the European Commission (BIO4-CT95-0291) and from Fundação para a Ciência e Tecnologia-Portugal (PRAXIS XXI/BD/13344/97 and BIO1117/95).
PY - 2008/3
Y1 - 2008/3
N2 - Chromatin remodeling, particularly histone acetylation, plays a critical role in the progression of pathological cardiac hypertrophy and heart failure. We hypothesized that curcumin, a natural polyphenolic compound abundant in the spice turmeric and a known suppressor of histone acetylation, would suppress cardiac hypertrophy through the disruption of p300 histone acetyltransferase- dependent (p300-HAT-dependent) transcriptional activation. We tested this hypothesis using primary cultured rat cardiac myocytes and fibroblasts as well as two well-established mouse models of cardiac hypertrophy. Curcumin blocked phenylephrin-induced (PE-induced) cardiac hypertrophy in vitro in a dose-dependent manner. Furthermore, curcumin both prevented and reversed mouse cardiac hypertrophy induced by aortic banding (AB) and PE infusion, as assessed by heart weight/BW and lung weight/BW ratios, echocardiographic parameters, and gene expression of hypertrophic markers. Further investigation demonstrated that curcumin abrogated histone acetylation, GATA4 acetylation, and DNA-binding activity through blocking p300-HAT activity. Curcumin also blocked AB-induced inflammation and fibrosis through disrupting p300-HAT-dependent signaling pathways. Our results indicate that curcumin has the potential to protect against cardiac hypertrophy, inflammation, and fibrosis through suppression of p300-HAT activity and downstream GATA4, NF-κB, and TGF-β-Smad signaling pathways.
AB - Chromatin remodeling, particularly histone acetylation, plays a critical role in the progression of pathological cardiac hypertrophy and heart failure. We hypothesized that curcumin, a natural polyphenolic compound abundant in the spice turmeric and a known suppressor of histone acetylation, would suppress cardiac hypertrophy through the disruption of p300 histone acetyltransferase- dependent (p300-HAT-dependent) transcriptional activation. We tested this hypothesis using primary cultured rat cardiac myocytes and fibroblasts as well as two well-established mouse models of cardiac hypertrophy. Curcumin blocked phenylephrin-induced (PE-induced) cardiac hypertrophy in vitro in a dose-dependent manner. Furthermore, curcumin both prevented and reversed mouse cardiac hypertrophy induced by aortic banding (AB) and PE infusion, as assessed by heart weight/BW and lung weight/BW ratios, echocardiographic parameters, and gene expression of hypertrophic markers. Further investigation demonstrated that curcumin abrogated histone acetylation, GATA4 acetylation, and DNA-binding activity through blocking p300-HAT activity. Curcumin also blocked AB-induced inflammation and fibrosis through disrupting p300-HAT-dependent signaling pathways. Our results indicate that curcumin has the potential to protect against cardiac hypertrophy, inflammation, and fibrosis through suppression of p300-HAT activity and downstream GATA4, NF-κB, and TGF-β-Smad signaling pathways.
UR - http://www.scopus.com/inward/record.url?scp=40549117477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40549117477&partnerID=8YFLogxK
U2 - 10.1172/JCI32865
DO - 10.1172/JCI32865
M3 - Article
C2 - 18292803
AN - SCOPUS:40549117477
SN - 0021-9738
VL - 118
SP - 879
EP - 893
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 3
ER -